In addition to standard anti-seizure medications that can be prescribed by general neurologists, there are specific treatments available for patients with rare epilepsy syndromes, such as Dravet syndrome and Lennox-Gastaut syndrome, which can only be prescribed through specialized epilepsy centers. These centers provide the necessary expertise and monitoring required for the safe and effective use of these advanced therapies.
Cannabidiol
Cannabidiol (CBD) is a next-generation anti-seizure medication, available as an oral solution. In the Czech Republic, CBD is approved as an add-on treatment for seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients aged 2 years and older, when used in combination with clobazam (CLB).
It is also approved as an adjunctive treatment for seizures related to tuberous sclerosis complex (TSC) in patients over 2 years of age, without the requirement for concurrent clobazam therapy.
Fenfluramin
Fenfluramin (FFA) is an anti-seizure medication approved as an add-on treatment for both pediatric and adult patients with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). It is administered as an oral solution.
Clinical studies have shown that more than half of patients with Dravet syndrome experienced a significant reduction in seizure frequency while using fenfluramine. In patients with LGS, the medication appears to be particularly effective in reducing drop attacks (seizures associated with sudden falls).
Because of its potential cardiovascular effects, regular echocardiographic (ECHO) monitoring of the heart is required during treatment with fenfluramine.
Need to schedule a follow-up appointment or running out of medication?
Adults +420 543 183 324
Children +420 532 234 917